SUBSCRIBE
SUBSCRIBE
News   Drug Development

Matrixx Initiatives, Inc. Says FDA Unwilling to Change Stance on Zicam

October 26, 2009 | 
1 min read
Reuters -- Matrixx Initiatives Inc said the U.S. health regulator has indicated that it is unwilling to reverse its position regarding the warning letter issued on company's nasal versions of Zicam cold remedy.
Clinical research Postmarket research
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Sanofi's Distribution Center in Quebec, Canada
Immunology and inflammation
Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study
September 5, 2025
 · 
2 min read
 · 
Tristan Manalac
halftone magazine style banner, dislike, negative rating, hand thumbs down
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
 · 
4 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH TACONIC BIOSCIENCES
The ‘Research Safety Net’ Saving Scientists from Funding Crisis
September 4, 2025
 · 
1 min read
 · 
Lori Ellis
Sea wave. Hand drawn realistic vector illustration in oriental vintage ukiyo-e style.
RNA editing
Wave Crashes Despite Successful RNA Editing in AATD Study
September 4, 2025
 · 
2 min read
 · 
Tristan Manalac